ASX Announcement 17 November 2026 First patient in India receives ReNerve’s NervAlign® Nerve Cuff Highlights • First patient in India treated with the NervAlign® Nerve Cu?, converting the Company’s CDSCO marketing 2 approval into clinical use • India is a major market opportunity for...
First patient in India receives NervAlign Nerve Cuff
Filed with ASX · · 3 pages · English
Summary by 6ix AI
ReNerve Limited has announced that the first patient in India has received its NervAlign® Nerve Cuff, marking a significant step in the product's commercial use following regulatory approval. This milestone was achieved in partnership with NetCentrix Ventures, highlighting India's potential as a major market for nerve repair solutions due to its large population and high incidence of related injuries. The announcement follows record sales for the September quarter, indicating strong growth for the company as it expands its presence in the Asia-Pacific region.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Story so far
Earlier from ReNerve
- Quarterly Investor Presentation
- Becoming a substantial holder
- Notification regarding unquoted securities - RNV
- Quarterly Report Webinar
- Q1 FY27 Activities Report and Appendix 4C
Later from ReNerve
All ReNerve news releasesFollow ReNerve into a list and get an email when it puts out news.
Follow ReNerve